Lactobacillus Plantarum 299v
ApprovedSmall molecule
Lactobacillus Plantarum 299v is one of 61 small molecule programs targeting Irritable Bowel Syndrome. It is currently in Approved.
2
Indications
3
Total Trials
1
Active Trials
60
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
185 competitors in Irritable Bowel Syndrome
#DrugCompanyPhaseTrials
1Lialda
TakedaPhase 3
Xifaxan
SSalix
Phase 3
Zofran
NovartisPhase 3
Amitiza
SSucampo Pharma Americas, LLC
Phase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Zarontin
PParkedale
Phase 3
Mesalazine
FerringPhase 3
Saccharomyces Boulardii
BBiocodex
Phase 3
Lactobacillus Plantarum 299v
UUniversity of Stellenbosch
Approved
Trulance
SSalix
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Diabetic Macular Edema1 trial
Irritable Bowel Syndrome1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity of Stellenbosch